Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials.

Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer. 1996 Jun 15; 77(12):2503-13.

View in: PubMed

subject areas

Adult
Aged
Breast Neoplasms
Carcinoma
Double-Blind Method
Fadrozole
Female
Humans
Megestrol
Menopause
Middle Aged
Prognosis
Prospective Studies
Survival Analysis

authors with profiles

Philip Bonomi